News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MGC Diagnostics Corporation Announces Worldwide Exclusive Distribution Partnership With Restech Respiratory Technology


3/19/2013 10:17:56 AM

SAINT PAUL, Minn., March 19, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology leader, today announced that it has entered into a worldwide distribution agreement with Restech Respiratory Technology (Restech Srl), a privately held company spun-off from the Politecnico di Milano, Italy, to market and distribute the Resmon Pro, Forced Oscillation Technique (FOT) device. Manufactured by Restech Srl, the Resmon Pro aids in the diagnosis and treatment of respiratory disease. Typically, the diagnosis of common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) involve complex measurements and maximum patient effort. Restech developed patented technology to determine the breath-by-breath presence and severity of expiratory flow limitation (EFL) during quiet breathing. Using the Resmon Pro, a physician can detect the presence, severity and reversibility of EFL, and evaluate the degree of airflow obstruction and shortness-of-breath experienced by the patient.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "Our agreement with Restech is an example of how MGC Diagnostics will execute strategic partnerships with emerging technology providers, both within the university sciences and entrepreneurial start-up sectors. Leveraging MGC Diagnostics global sales, marketing, and support network provides emerging technology companies best-in-class access to cardiorespiratory healthcare professionals and their patients throughout the world."

About Restech Respiratory Technology

Restech SRL is a spinoff company of Politecnico di Milano derived from a Bioengineering Department research team of the Biomedical Technology Laboratory (TBMLab). Their primary focus is in the development of innovative products and services for the diagnosis, monitoring and management of patients affected by respiratory diseases.

About MGC Diagnostics

MGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forwardlooking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forwardlooking statements, the Company claims the protection of the safe harbor for forwardlooking statements contained in federal securities laws. These forwardlooking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forwardlooking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe Diaz


MGC Diagnostics Corporation

Lytham Partners, LLC


Chief Executive Officer

(602) 889-9700


(651) 484-4874

mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES